ChemicalBook Chinese  Japanese  Germany

ChemicalBook >> CAS DataBase List >> Orlistat

Orlistat

Indications and Usage Mechanism of Action Pharmacokinetics Drug Interactions Side Effects Warnings and Precautions

CAS No.96829-58-2
Chemical Name:Orlistat
Synonyms:XENICAL;oristat;Olistat;ORLISTAT;Orlistate;Orlipastat;RO-18-0647;ORLIPASTATUM;Ro 18-0647/002;Orlistat Powder
CBNumber:CB2431985
Molecular Formula:C29H53NO5
Formula Weight:495.73
MOL File:96829-58-2.mol
Orlistat Property
Melting point : <50 °C
storage temp. : 2-8°C
solubility : DMSO: 19 mg/mL
form : solid
color : white
CAS DataBase Reference: 96829-58-2(CAS DataBase Reference)
Safety
WGK Germany : 3
RTECS : OH3167600
Hazardous Substances Data: 96829-58-2(Hazardous Substances Data)

Orlistat Chemical Properties,Usage,Production

Indications and Usage
Orlistat is an internationally recognized new form of weight loss drug. Its commercial name is Sainike and first went on sale in New Zealand in 1998. Orlistat is a long-term and highly effective specific gastrointestinal lipase inhibitor, and it is insoluble in water, soluble in chloroform, and easily soluble in ethanol.
Orlistat can be used clinically to treat obesity. Usually, a dose of 120mg is taken three times a day within one hour of a meal. Weight loss begins to occur after two weeks of usage. It can be used continuously for 6-12 months, and its effects will cease to increase after daily dosage exceeds 400mg. This drug is suitable to be used in combination with a low-calorie diet by obese and overweight individuals, and it can also be used as long-term treatment for patients who have faced weight-related risk factors. Orlistat has a long-term weight-control effect that reduces and maintains weight and prevents against rebounding. Using Orlistat can lower the occurrences of weight-related risk factors and diseases, including hypercholesterolemia, type-2 diabetes, impaired glucose tolerance, hyperinsulinemia, and hypertension, and it can reduce the fat content in organs. Orlistat also adjusts blood lipid levels: it can decrease serum triglycerides (TG) and low density lipoprotein cholesterol (LDL-C), and it can increase the ratio of high density lipoproteins to low density lipoproteins in obese patients.
Mechanism of Action
Orlistat is a type of lipase inhibiting weight loss drug and is a hydrated derivative of lipostatin. Orlistat effectively and selectively inhibits stomach lipase and pancreatic lipase, while having no impact on other digestive enzymes (such as amylase, trypsin and chymotrypsin) and on phospholipase, nor does it affect the absorption of carbohydrates, protein and phospholipids. This drug is not absorbed though the gastrointestinal tract and has a reversible inhibiting effect on lipase. Orlistat deactivates enzymes by covalent binding to the serine residue on the active sites of stomach and pancreatic lipase. This prevents the fat in food from being broken down into free fatty acids and diacylglycerol, so it cannot be absorbed, lowering caloric intake and therefore controlling body weight. This drug does not need to be absorbed by the entire body to take effect. Orlistat’s pharmacological activity is dose dependent: a treatment dosage of Orlistat (120mg/d, tid, taken with meals), combined with a low-calorie diet, can reduce up to 30% of fat absorption. In a study comparing normal and obese volunteers, Orlistat was basically not absorbed by the body at all and had a very low blood concentration. After a single oral dosage (the largest being 800mg), the blood concentration of Orlistat in the following 8 hours was <5 ng/ml. Typically, a treatment dosage of Orlistat is only minimally absorbed by the body and will not accumulate in a short treatment period. In an in vitro experiment, Orlistat’s binding rate with other serum proteins exceeded 99% (bound proteins were mainly lipoproteins and albumin), and its binding rate with red blood cells was very low.
Pharmacokinetics
Minimal absorption when ingested orally, can be metabolized and deactivated in the intestinal tract, metabolizing area is the stomach wall, clearing half-life is about 14-19 hours. A study of obese patients showed that the essentially unabsorbed Orlistat produced two main metabolites in blood: M1(4 lactone ring hydrolysate) and M3 (M1 adhered to an N-leucine cleavage product) compose 42% of total blood concentration. M1 and M3 have extremely weak inhibiting effects on lipase and can both be excreted through bile. About 97% of the drug is excreted through feces, 83% of which is excreted in its original form. The cumulative renal output of Orlistat and its metabolites is lower than 2%, and the complete excretion of the drug (through feces and urine) requires 3-5 days.
Drug Interactions
May reduce absorption of vitamin A, D and E; take supplements when using this drug. Any preparations containing vitamin A, D or E (such as compound vitamin preparations), should be taken 2 hours after this drug or before bed.
Type-2 diabetes patients may need to decrease dosage of antidiabetic drugs (such as sulfonylurea).
Combined use with cyclosporine may lower the blood concentration of the latter drug.
Combined use with amiodarone may reduce absorption of the latter drug, thus decreasing its curative effects.
Side Effects
There have been rare cases of Orlistat use leading to elevated transaminase, elevated alkaline phosphatase, and severe hepatitis. There have also been cases of liver failure, some of which required liver transplant surgery or led to death. Orlistat has also had rare reports of allergic reactions, mostly including itchiness, rashes, hives, neurovascular edema, bronchospasm and allergic reactions, as well as very rare reports of herpes. Monitoring of sales also found reports of pancreatitis.
Warnings and Precautions
Orlistat has led to rare cases of acute hepatocellular necrosis and acute liver failure, some of which required liver transplants or led to death. Thus, prescribing physicians must inform patients to immediately cease use of Orlistat and other suspicious drugs and seek inspection for liver functions if any symptoms or signs of liver function abnormalities occur (such as reduced appetite, itchiness, jaundice, dark urine, light feces, or pain in the upper right quadrant).
Chemical Properties
Off-White Solid
Uses
An antiobesity agent. A pancreatic lipase inhibitor. Antiobesity agent.
Uses
antidiabetic
Uses
Orlistat is an antiobesity agent. Orlistat is an pancreatic lipase inhibitor.
Uses
Tetrahydrolipstatin (orlistat) is a semi-synthetic derivative of lipstatin, a metabolite isolated from Streptomyces toxytricini. Tetrahydrolipstatin acts as a potent, irreversible inhibitor of pancreatic lipase. In vivo, it blocks the absorption of triglycerides while allowing fatty acid absorption. Tetrahydrolipstatin is widely used for the treatment of obesity.
Biological Activity
Hypolipemic pancreatic, gastric and carboxylester lipase inhibitor. Exhibits no activity at phospholipase A 2 , liver esterase, trypsin and chymotrypsin. Inhibits the thioesterase domain of fatty acid synthase, leading to cell cycle arrest at the G 1 /S boundary in vitro . Prevents the absorption of approximately one third of fat from food and exhibits progastrokinetic, antiobesity and antihypercholesterolemic activity in vivo .
Orlistat Preparation Products And Raw materials
Raw materials
Preparation Products
Orlistat Suppliers      Global( 237)Suppliers     
Supplier Tel Fax Email Country ProdList Advantage
Capot Chemical Co.,Ltd.
+86 (0)571-855 867 18
+86 (0)571-858 647 95sales@capotchem.com China 19954 60
Shenzhen Sendi Biotechnology Co.Ltd.
0755-23311925 18102838259
0755-23311925Abel@chembj.com CHINA 3226 55
Nanjing Sunlida Biological Technology Co., Ltd. 025-58378339;025-57798810
025-57019371sales@sunlidabio.com China 3866 55
Guangzhou Isun Pharmaceutical Co., Ltd 020-39119399 18927568969
020-39119999isunpharm@qq.com, isunpharm@hotmail.com China 4935 55
XiaoGan ShenYuan ChemPharm co,ltd Tell:86-712-2580635 Mobile:15527768850 . 15527768836
86-712-2580625 QQ:1623551145sales02@farchem.com China 9241 52
Taizhou DongBang Fine Chemical Co. Ltd. +86-0523-86235448 15996000437
+86-0523-862354482535251509@qq.com China 48 55
Wuhan Runzeweiye Technology Co., Ltd. 027-50779735 15172337137 QQ:940329747
027-50779735runzeweiye999@163.com China 797 55
Wuhan Wsem Biological Co., Ltd. 027-59402396
027-5940239613419635609@163.com China 1005 55
J & K SCIENTIFIC LTD. 400-666-7788 +86-10-82848833
+86-10-82849933jkinfo@jkchemical.com;market6@jkchemical.com China 96832 76
Meryer (Shanghai) Chemical Technology Co., Ltd. +86-(0)21-61259100(Shanghai) +86-(0)755-86170099(ShenZhen) +86-(0)10-62670440(Beijing)
+86-(0)21-61259102(Shanghai) +86-(0)755-86170066(ShenZhen) +86-(0)10-88580358(Beijing)sh@meryer.com China 40403 62
 
96829-58-2(Orlistat)Related Search:
Sibutramine hydrochloride Sibutramine N-FORMYL-L-LEUCINE (2S,3S,5S)-5-[(N-Formyl-L-leucyl)oxy]-2-hexyl-3-hydroxyhexadecanoic Acid (Orlistat Impurity) Orlistat-d3 Orlistat Impurity,(2S,3R,5S)-5-[(N-Formyl-L-leucyl)oxy]-2-hexyl-3-hydroxyhexadecanoic Acid (Orlistat Impurity) BETA-BUTYROLACTONE Orlistat Methyl Methanol 1,2-EPOXYTETRADECANE Basic Violet 1 L-tert-Leucine Methyl acrylate Acetonitrile Dodecyl alcohol Kresoxim-methyl Methylparaben
(S)-2-FORMYLAMINO-4-METHYL-PENTANOIC ACID (S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]-DODECYL ESTER RO-18-0647 (-)-TETRAHYDROLIPSTATIN ORLISTAT N-FORMYL-L-LEUCINE (1S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]DODECYL ESTER Enzyme Inhibitors by Enzyme Enzymes, Inhibitors, and Substrates Enzyme Inhibitors XENICAL L to O Lipase, Pancreatic BioChemical Biochemicals and Reagents 96829-58-2 (-)-Tetrahydrolipstatin(EquivalentToOrlistat) C29H53NO5 Orlipastat Xenical, (-)-Tetrahydrolipstatin, N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl Ester, Orlistate Pharmaceutical Raw Materials Orlistat, Tetrahydolipstat ORLIPASTATUM Miscellaneous Biochemicals (-)-Tetrahydrolipstatin API Antiobesity Agent C25H53NO3 Ro 18-0647/002 Chiral Reagents Intermediates & Fine Chemicals Pharmaceuticals (-)-Tetrahydrolipstatin, Ro-18-0647, N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester L-Leucine, N-formyl-, (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester N-Formyl-L-leucine (1S)-1-[[(2S)-3α-hexyl-4-oxooxetan-2β-yl]methyl]dodecyl ester N-Formyl-L-leucine (S)-1-[[(2S)-3α-hexyl-4-oxooxetane-2β-yl]methyl]dodecyl ester Orlistat,()-Tetrahydrolipstatin, N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester, Ro-18-0647 Orlistat (200 mg) ORLISTAT (BULK MATERIAL) ORLISTAT PELLETS 50% Amino Acids & Derivatives Heterocycles Orlistat(synthesis) Orlistat(FerMentation) (S)-2-FORMYLAMINO-4-METHYL-PENTANOIC ACID (S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]-DODECYL ESTER S,S,S,S-Orlistat (2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl (2S)-2-forMaMido-4-Methylpentanoate oristat ACTOS Orlipastat, Orlistat Other APIs N-formyl-(1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester L-Leucine Orlistat N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester Lipid-lowering medicine reducing weight Orlistat Powder Orlistat, >=98% Olistat Lipase Inhibitor, THL
Copyright 2016 © ChemicalBook. All rights reserved